| The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine (NCT05279248) | Zhejiang Provincial Center for Disease Control and Prevention | 2021-08-25 |
| Clinical Trial to Evaluate the Safety and Immunogenicity of Mumps Vaccine (NCT04364399) | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 2020-11-18 |
| Safety Study of Live Attenuated Mumps Vaccines in Junior High School Students Under 14 Years Old (NCT05145166) | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 2020-10-06 |
| Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine (NCT02880865) | PATH | 2016-10-13 |
| Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine (NCT03160820) | Centers for Disease Control and Prevention, China | 2016-03-01 |
| Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants (NCT02692599) | Sinovac (Dalian) Vaccine Technology Co., Ltd. | 2016-01-01 |
| Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants (NCT05065177) | Sinovac Research and Development Co., Ltd. | 2016-01-01 |
| Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR (NCT02325310) | Assistance Publique - Hôpitaux de Paris | 2015-02-04 |
| Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12-15 Months of Age, Followed by Tetraviral Vaccine in Children 15-18 Months. (NCT01991899) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2015-02-01 |
| Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older (NCT02058563) | GlaxoSmithKline | 2014-07-01 |
| Safety Study of Measles-Mumps-Rubella-Varicella (MMRV) Vaccine, Priorix-Tetra™ in Children Living in the Philippines (NCT01738841) | GlaxoSmithKline | 2013-08-01 |
| Consistency Study of GlaxoSmithKline (GSK) Biologicals' MMR Vaccine (209762) (Priorix) Comparing Immunogenicity and Safety to Merck & Co., Inc.'s MMR Vaccine (M-M-R II), in Children 12 to 15 Months of Age (NCT01702428) | GlaxoSmithKline | 2012-11-09 |
| Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life (NCT01681992) | GlaxoSmithKline | 2012-10-10 |
| A Phase I, Safety Study of Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in Chinese Children (NCT01712906) | Institute of Medical Biology, Chinese Academy of Medical Sciences | 2012-10-01 |
| Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single Dose and Multidose Presentations (NCT01777529) | The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz) | 2012-10-01 |
| Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)(V221-027) (NCT01536405) | Merck Sharp & Dohme LLC | 2012-06-05 |
| Immunogenicity and Safety Study of PriorixTetra™ When Co-administered With Conjugated MenC Vaccine in Healthy Children (NCT01506193) | GlaxoSmithKline | 2012-02-06 |
| Special Drug Use Investigation for Botox® (Botulinum) Spasticity (BOTOX is a Registered Trademark of Allergan, Inc.) (NCT01390922) | GlaxoSmithKline | 2011-08-01 |
| Making Decisions About the Measles-Mumps-Rubella Vaccine (NCT01369394) | University of Michigan | 2011-06-01 |
| Study of Japanese Encephalitis Chimeric Virus Vaccine Given With Measles-Mumps-Rubella Vaccine in Taiwanese Toddlers (NCT01188343) | Sanofi Pasteur, a Sanofi Company | 2010-08-01 |
| Measles, Mumps, and Rubella (MMR) Immunity in College Students (NCT00962819) | Sri Edupuganti, MD MPH | 2010-03-01 |
| Comparison of GSK Measles-mumps-rubella-varicella (MMRV) Vaccine Versus PriorixTM (NCT00969436) | GlaxoSmithKline | 2009-11-09 |
| Immunogenicity of GSKs' MMR Vaccine (209762) vs. M-M-R® II, When Given With Routine Vaccines at 12-15 Months of Age (NCT00861744) | GlaxoSmithKline | 2009-06-03 |
| Immunogenicity & Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds (NCT00892775) | GlaxoSmithKline | 2009-06-03 |
| The Influence of Probiotics on the Immunologic Response to Vaccinations in Infants (NCT00645996) | Assaf-Harofeh Medical Center | 2008-03-01 |
| A Study of ProQuad™ in Healthy Children in Korea (V221-023) (NCT00839917) | Merck Sharp & Dohme LLC | 2008-02-01 |
| Comparative Study of Immunogenicity and Safety of a 2-dose Regimen of ProQuad® Manufactured With rHA (V221-038) (NCT00566527) | Merck Sharp & Dohme LLC | 2007-11-29 |
| Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine vs. ProQuad® in Children 12-14 Months of Age (NCT00578175) | GlaxoSmithKline | 2007-11-20 |
| Safety Study of ProQuad® rHA in Infants (V221-037) (NCT00560755) | Merck Sharp & Dohme LLC | 2007-10-24 |
| Study of the Safety of Menactra® Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers (NCT00483574) | Sanofi Pasteur, a Sanofi Company | 2007-05-01 |
| Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study (V251-066)(COMPLETED) (NCT00326183) | Merck Sharp & Dohme LLC | 2007-03-26 |
| Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease (NCT00932269) | Swedish Institute for Infectious Disease Control | 2007-03-01 |
| Immunogenicity and Safety Study of Proquad® and Infanrix® Hexa When Administered Concomitantly (V221-035) (NCT00432042) | Merck Sharp & Dohme LLC | 2007-01-12 |
| Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra® in Healthy Toddlers (NCT00422292) | Sanofi Pasteur, a Sanofi Company | 2006-12-01 |
| ProQuad® Intramuscular vs Subcutaneous (NCT00402831) | Merck Sharp & Dohme LLC | 2006-10-06 |
| A Study of 2 Doses of Menactra®, a Meningococcal Conjugate Vaccine in Healthy Toddlers (NCT00384397) | Sanofi Pasteur, a Sanofi Company | 2006-09-01 |
| Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine (NCT00313950) | Sanofi Pasteur, a Sanofi Company | 2006-09-01 |
| Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ (NCT00352898) | GlaxoSmithKline | 2006-04-01 |
| Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes (NCT00351923) | GlaxoSmithKline | 2006-03-01 |
| Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix™ Given With Varilrix™ (NCT00353288) | GlaxoSmithKline | 2006-03-01 |
| V221 Concomitant Use Study With Pneumococcal Conjugate Vaccine (V221-019) (NCT00109343) | Merck Sharp & Dohme LLC | 2006-03-01 |
| Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases (NCT00127010) | GlaxoSmithKline | 2005-11-01 |
| Immune Responses to Two Dose Varivax +/- MMR-II (NCT00258726) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-10-01 |
| Immunogenicity and Safety of Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases (NCT00126997) | GlaxoSmithKline | 2005-05-01 |
| Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases (NCT00127023) | GlaxoSmithKline | 2005-05-01 |
| Immunogenicity and Safety of Concomitant Administration of MMR™ rHA and VARIVAX® by Intramuscular Versus Subcutaneous Route (V205C-011) (NCT00432523) | Merck Sharp & Dohme LLC | 2005-01-20 |
| Safety Study of a Refrigerator-stable Formulation of VARIVAX® (NCT00432731) | Merck Sharp & Dohme LLC | 2004-12-01 |
| Long-term Follow-up on Immunogenicity & Safety of Measles-Mumps-Rubella-Varicella (MMRV) Combined Vaccine (NCT00406211) | GlaxoSmithKline | 2004-07-01 |
| Responses of Premature Infants to Measles-Mumps-Rubella (MMR) and Varicella Vaccines (NCT00138255) | National Institute of Allergy and Infectious Diseases (NIAID) | 2004-06-01 |
| MMR and Varicella Vaccine in Premature Infants (NCT00156559) | University of Rochester | 2004-01-01 |
| Study to Evaluate Frozen Versus Refrigerated MMRV (Combined Measles, Mumps, Rubella, and Varicella) Investigational Vaccine (V221-016) (NCT00092430) | Merck Sharp & Dohme LLC | 2002-09-26 |
| Safety, Tolerability, and Immunogenicity of an Investigational Vaccine With Recombinant Human Albumin (rHA) in Children 12 to 18 Months of Age (V205C-009)(COMPLETED) (NCT00092404) | Merck Sharp & Dohme LLC | 2001-12-01 |
| Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore. (NCT00388440) | GlaxoSmithKline | 2000-11-01 |
| A Study of ProQuad in Healthy 4 to 6 Year Old Children (V221-014) (NCT00985166) | Merck Sharp & Dohme LLC | 2000-08-01 |
| Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines (NCT00984295) | Merck Sharp & Dohme LLC | 2000-06-01 |
| Safety, Tolerability, and Immunogenicity of 3 Frozen ProQuad Consistency Lots in Healthy Children (V221-012)(COMPLETED) (NCT00985153) | Merck Sharp & Dohme LLC | 2000-03-01 |
| ProQuad Dose Selection Study (V221-011)(COMPLETED) (NCT00986232) | Merck Sharp & Dohme LLC | 1999-04-01 |
| A Study of An Approved Vaccine at Mumps Expiry Potency in Healthy Children 12 to 18 Months of Age (V205C-007)(COMPLETED) (NCT00092391) | Merck Sharp & Dohme LLC | 1999-02-01 |
| ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED) (NCT00975507) | Merck Sharp & Dohme LLC | 1998-03-01 |